GLP-1s exploded seemingly out of nowhere, straining pharmacy plan bottom lines. Psoriasis treatments don't have to follow the ...

French pharma major Sanofi delivered a set of first-quarter financial results that seemed to satisfy markets Thursday, as its ...

Regeneron Pharmaceuticals Inc (REGN) reports robust growth in Dupixent sales and strategic R&D investments, while navigating ...

Q1 sales rose 10.8% to $10.42 billion, exceeding estimates on strength in Dupixent and new pharma products. Operating income climbed 20.1% to $3.06 billion, driven by innovation and favorable launch ...

Management projected significant growth opportunities across its portfolio, led by Dupixent for COPD and upcoming ... to reduced general administrative costs. Free cash flow for Q1 2025 was ...